Advaxis is leveraging its Lm Technology™ to target common (public or shared) mutations (hotspots) in tumor driver genes, in a program referred to as ADXS-HOT. The ADXS-HOT program is a series of cancer-specific drug candidates that will target common, or shared, somatic mutations, cancer testis antigens and oncofetal antigens. Advancement of the proprietary ADXS-HOT preclinical program will expand Lm Technology into multiple products targeting several of the most common cancers.
ADXS-HOT products may target acquired public mutations in tumor driver genes that are shared by multiple patients, and could have greater immunogenicity than the natural sequence peptides in normal cells. DNA sequencing is not required, and the ADXS-HOT products are expected to be “off the shelf” and ready to administer for multiple patients.
Advaxis is currently prioritizing product development in the most prevalent cancers, with the first indication planned to be Non Small Cell Lung Cancer. An IND for ADXS-503, has been allowed and the first site was initiated in February 2019. We plan to file two more INDs in 2019, including prostate and bladder cancer.